ECSP16062174A - Análogos de cortistatina y síntesis y usos de los mismos - Google Patents

Análogos de cortistatina y síntesis y usos de los mismos

Info

Publication number
ECSP16062174A
ECSP16062174A ECIEPI201662174A ECPI201662174A ECSP16062174A EC SP16062174 A ECSP16062174 A EC SP16062174A EC IEPI201662174 A ECIEPI201662174 A EC IEPI201662174A EC PI201662174 A ECPI201662174 A EC PI201662174A EC SP16062174 A ECSP16062174 A EC SP16062174A
Authority
EC
Ecuador
Prior art keywords
formula
found
compound
cortistatin
potent
Prior art date
Application number
ECIEPI201662174A
Other languages
English (en)
Inventor
Ramharter Juergen
D Shair Matthew
Young Ahn Jae
Efrem Pelish Henry
Bor-Jen Liau Brian
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of ECSP16062174A publication Critical patent/ECSP16062174A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[0001] Se proporcionan en la presente nuevos análogos de cortistatina de la fórmula (A), (B) y (C), y sales farmacéuticamente aceptables, sales de amina cuaternaria, y N-óxidos de los mismos, sintetizados, en parte, por aminación reductiva de una cetona de la Fórmula (B) para proporcionar el producto aminado de la fórmula (A), como se representa en el Esquema 1, opcionalmente a través de un intermedio de imina de la fórmula (C). [0002] Además, se proporcionan nuevos análogos de cortistatina preparados por reducción de la cetona de la fórmula (B) para proporcionar un compuesto C3-hidroxilo de la Fórmula (D). Además se proporciona un compuesto de la fórmula (E), preparado por sustitución del compuesto de la Fórmula (D). Tales compuestos también se pueden convertir en un compuesto de la Fórmula (A) por tratamiento con una amina en condiciones adecuadas. [0003] Se ha encontrado sorprendentemente que los isómeros beta de la Fórmula (A), que se conoce como la Fórmula (A-1), se han encontrado como equipotentes, o más potentes, que la cortistatina A en la inhibición de la actividad de la quinasa CDK8 y la proliferación de las células AML, y también se ha encontrado que los isómeros alfa correspondientes de la fórmula (A), que se refiere como la Fórmula (A-2), también son muy potentes. Además, se ha descubierto que los compuestos de la Fórmula (B) se han encontrado activos contra el crecimiento de líneas celulares AML en cultivo y actividad de la quinasa CDK8 en las c
ECIEPI201662174A 2013-12-24 2016-07-20 Análogos de cortistatina y síntesis y usos de los mismos ECSP16062174A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US201461993329P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
ECSP16062174A true ECSP16062174A (es) 2018-12-31

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201662174A ECSP16062174A (es) 2013-12-24 2016-07-20 Análogos de cortistatina y síntesis y usos de los mismos

Country Status (30)

Country Link
US (3) US9994582B2 (es)
EP (2) EP3087080B1 (es)
JP (2) JP6494631B2 (es)
KR (1) KR20160101162A (es)
CN (2) CN106103452B (es)
AP (1) AP2016009324A0 (es)
AU (2) AU2014369834B2 (es)
BR (1) BR112016014760A2 (es)
CA (1) CA2934819A1 (es)
CL (1) CL2016001631A1 (es)
CR (1) CR20160291A (es)
DO (1) DOP2016000158A (es)
EA (2) EA030907B1 (es)
EC (1) ECSP16062174A (es)
ES (1) ES2709480T3 (es)
GT (1) GT201600135A (es)
IL (1) IL246390A0 (es)
MD (1) MD20160089A2 (es)
MX (1) MX361652B (es)
MY (1) MY180383A (es)
NI (1) NI201600089A (es)
PE (1) PE20161405A1 (es)
PH (1) PH12016501258A1 (es)
RU (1) RU2016126503A (es)
SA (1) SA516371410B1 (es)
SG (2) SG10201808151RA (es)
SV (1) SV2016005234A (es)
TN (1) TN2016000240A1 (es)
WO (1) WO2015100420A1 (es)
ZA (1) ZA201603894B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709480T3 (es) 2013-12-24 2019-04-16 Harvard College Análogos de cortistatina y síntesis y usos de los mismos
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP2018516884A (ja) * 2015-05-08 2018-06-28 プレジデント アンド フェローズ オブ ハーバード カレッジ コルチスタチン誘導体による治療に対する患者の標的化選択
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) * 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
WO2017087608A1 (en) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
WO2017112823A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Targeted selection of patients for treatment with specific cortistatin derivatives
CA3009324A1 (en) * 2015-12-23 2017-06-29 President And Fellows Of Harvard College Cortistatin analogs and uses thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US20190062340A1 (en) * 2016-02-19 2019-02-28 President And Fellows Of Harward College Cortistatin analogs
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
EP3575297B1 (en) 2017-01-30 2024-12-18 Kyoto University Novel compound, and method for producing regulatory t cells
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
KR20200053481A (ko) 2017-07-24 2020-05-18 비타이 파마슈티컬즈, 엘엘씨 RORγ의 억제제
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
JP7628252B2 (ja) * 2019-02-01 2025-02-10 ユニヴァーシティー オブ サウスカロライナ 二環式ピリジン組成物およびがんの治療にそれを使用する方法
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19
CA3234008A1 (en) 2021-09-27 2023-03-30 Kyoto University Method for producing t cell
EP4438048A4 (en) 2021-11-24 2025-10-22 Regcell Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES
CA3239019A1 (en) 2021-11-24 2023-06-01 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
WO2023182328A1 (ja) 2022-03-23 2023-09-28 国立大学法人京都大学 制御性ｔ細胞の製造方法
WO2024071010A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 Ｔ細胞の製造方法
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
JPWO2024166969A1 (es) 2023-02-08 2024-08-15
TW202506995A (zh) 2023-03-29 2025-02-16 日商雷格細胞股份有限公司 人類誘導性調節性ｔ細胞及其製作方法、以及用於治療或預防ｔ細胞相關疾患的醫藥組成物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
IL146223A0 (en) 1999-04-30 2002-07-25 Arch Dev Corp Steroid derivatives
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP5420128B2 (ja) 1999-10-13 2014-02-19 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン ヘッジホッグ経路の調節物質、並びにそれに関する組成物及び利用法
ATE413179T1 (de) 1999-10-25 2008-11-15 Hollis Eden Pharmaceuticals Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
AU2003208913A1 (en) 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2004058795A1 (en) 2002-12-24 2004-07-15 The University Of British Columbia Angiogenic compounds and uses thereof
EA011123B1 (ru) 2003-03-24 2008-12-30 Стерикс Лимитед Производные эстрогена в качестве ингибиторов стероидной сульфатазы
AU2004275693A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
CN100448863C (zh) * 2003-07-24 2009-01-07 默克公司 抗生素化合物
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
EA019560B1 (ru) 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)
CA2635370A1 (en) 2006-01-09 2007-07-09 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
WO2007133491A1 (en) * 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
KR20090101278A (ko) 2006-12-22 2009-09-24 인더스트리얼 리서치 리미티드 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체
BRPI0808444A2 (pt) 2007-03-07 2017-06-06 Infinity Discovery Inc análogos de ciclopamina lactam e métodos de uso dos mesmos
US8604004B2 (en) * 2007-10-04 2013-12-10 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
WO2009137335A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute Synthesis of (+) corstistatin a and related compounds
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
EP2421882A4 (en) 2009-04-22 2013-05-08 Harvard College ANGIOGENESIS INHIBITORS
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
KR20130083386A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
ES2570748T3 (es) 2010-09-17 2016-05-20 Univ Osaka Nuevo análogo de cortistatina A y uso del mismo
US20130331414A1 (en) 2011-01-10 2013-12-12 Susana Valente Inhibitors of Retroviral Replication
US9321737B2 (en) 2012-02-02 2016-04-26 Senex Biotechnology Inc CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014134169A1 (en) 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
US20160208246A1 (en) 2013-06-10 2016-07-21 Yeda Research And Development Co. Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
MY185593A (en) 2013-09-18 2021-05-24 Bcn Peptides Sa Cortistatin analogues for the treatment of inflammatory and/or immune diseases
ES2709480T3 (es) * 2013-12-24 2019-04-16 Harvard College Análogos de cortistatina y síntesis y usos de los mismos

Also Published As

Publication number Publication date
US10508121B2 (en) 2019-12-17
SG11201605178WA (en) 2016-07-28
CN106103452B (zh) 2019-05-21
EP3505521A1 (en) 2019-07-03
AP2016009324A0 (en) 2016-07-31
MX2016008436A (es) 2016-12-16
WO2015100420A1 (en) 2015-07-02
PE20161405A1 (es) 2017-01-18
EA201891279A1 (ru) 2019-01-31
RU2016126503A3 (es) 2018-07-17
MD20160089A2 (ro) 2016-12-31
MX361652B (es) 2018-12-13
EP3087080A1 (en) 2016-11-02
EP3087080B1 (en) 2018-11-28
JP2019108367A (ja) 2019-07-04
MY180383A (en) 2020-11-28
ES2709480T3 (es) 2019-04-16
US20180319814A1 (en) 2018-11-08
SG10201808151RA (en) 2018-10-30
KR20160101162A (ko) 2016-08-24
EA030907B1 (ru) 2018-10-31
BR112016014760A2 (pt) 2017-12-12
DOP2016000158A (es) 2016-10-16
AU2019201888A1 (en) 2019-04-11
JP6494631B2 (ja) 2019-04-03
AU2014369834A1 (en) 2016-06-23
TN2016000240A1 (en) 2017-10-06
ZA201603894B (en) 2018-08-29
RU2016126503A (ru) 2018-01-30
CL2016001631A1 (es) 2017-02-24
AU2014369834B2 (en) 2018-12-20
CA2934819A1 (en) 2015-07-02
US20190185484A1 (en) 2019-06-20
NI201600089A (es) 2016-08-18
EA201691167A1 (ru) 2016-11-30
SA516371410B1 (ar) 2019-02-13
US10273241B2 (en) 2019-04-30
US9994582B2 (en) 2018-06-12
SV2016005234A (es) 2018-12-14
IL246390A0 (en) 2016-08-31
GT201600135A (es) 2018-11-27
US20170029435A1 (en) 2017-02-02
PH12016501258A1 (en) 2016-08-15
JP2017509586A (ja) 2017-04-06
CR20160291A (es) 2017-02-24
CN110183461A (zh) 2019-08-30
CN106103452A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
ECSP16062174A (es) Análogos de cortistatina y síntesis y usos de los mismos
DOP2019000030A (es) Inhibidores de cdk2/4/6
MX2022005610A (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
UY34530A (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
UY35185A (es) ?Derivados de 4-(bifenil-3-il)-7H-imidazo[4,5-c]piridazina?.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
UY32574A (es) Antagonistas del receptor cxcr3
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
IN2014DN00090A (es)
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
WO2016125190A3 (en) Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones